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Cancer is one of the major causes of death worldwide and one of the factors associated with this is the 
therapeutic failure. Recently there has been an increasing interest in designing personalized therapies 
based on patient’s genotype. Glutathione–S-Transferase genes GSTT1, GSTM1 and GSTP1 genes help in 
detoxification of various genotoxic agents such as cyclophosphamide, an indirect alkylating agent that 
damages the chemical structure of DNA. It is widely used with other drugs in the treatment of various 
cancers. Determine whether the extent of DNA damage evaluated by the comet assay performed in vitro by 
cyclophosphamide in lymphocytes is modulated by polymorphisms of GSTT1, GSTM1 and GSTP1. 
Lymphocytes from 120 healthy donors were treated with a single concentration of cyclophosphamide and 
the extent of DNA damage was evaluated by a modified comet assay. Polymorphisms of GSTT1 and GSTM1 
were identified by end-point polymerase chain reaction, while GSTP1 alleles were identified by PCR-RFLP. 
A great variability in the response to cyclophosphamide was found among individuals. Only 12 individuals 
from all the volunteer donors showed to have the complete wild genotype (GSTT1, GSTM1, GSTP1Ile/Ile105, 
Ala/Ala114) and coincidentally, this was the group with the lowest cyclophosphamide produced DNA 
damage. The differences in tail length between this “wild type group” and the other 11 genotypes 
recognized were statistically significant, suggesting a relation between GST genotype and 
cyclophosphamide induced DNA damage modulation.  
 





Cyclophosphamide is a drug used to treat some types of 
cancer. It is an alkylating cytostatic agent, with a broad 
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therapeutic  treatment  of breast carcinoma, acute 
lymphoblastic leukemia, Burkitt's lymphoma, multiple 
myeloma, ovarian and lung sarcoma, retinoblastoma, 
neuroblastoma, among others (Moore, 1991). This drug 
exerts its effect by disrupting DNA, which leads to cell 
death, resulting on the one hand, in the control of the 
disease and on the other, in a lot of secondary effects. It  




is nitrogen mustard with the chemical structure of a 
substituted oxazaphosphorine which requires to be 
activated by the hepatic microsomal enzyme system in 
order to be cytotoxic (Garibay et al., 2015). 
The liver enzymes convert cyclophosphamide first into 
4 hydroxycyclophosphamide, then into aldophosphamide 
and finally into phosphoramide mustard, which is the 
metabolite with alkylating effects on DNA (Emadi et la., 
2009). During that metabolic activation, involving the alkyl 
and nucleophilic sites of DNA, adducts are formed. 
Alkylation products are important in the biological effects 
caused by this and other alkylating agents. It is a strong 
bone marrow depressant, which is the biggest toxic 
effect, leading to a dose related suppression of 
myelopoiesis, directly attacking the bone marrow. 
Lymphoid proliferative cells are destroyed, but some 
resting cells can also be attacked (García et al., 1988; 
Emadi et al., 2009; Garibay et al., 2015). 
Glutathione S-transferases (GSTs), comprise a family 
of phase II metabolic isozymes best known for their ability 
to catalyze the conjugation of the reduced form of 
glutathione (GSH) to xenobiotic substrates for the 
purpose of detoxification. The GSTs expression plays an 
important protective effect role on determination the 
cytotoxicity of chemotherapeutic drugs (Soto et al., 2011). 
The most studied GST subclasses in mammals are Mu 
(µ), Pi (π), Theta (θ) and GSTO (ω) (Hayes and Strange, 
2000; Hayes et al., 2004). Each class of GSTs has 
different isoforms codified by several polymorphic genes. 
The π class by the GSTP1 gene, the θ class by two 
alleles GSTT1 and GSTT2, and µ class by five genes: 
GSTM1, GSTM2, GSTM3, GSTM4 and GSTM5 (Pemble 
et al., 1987; Moore, 1991; Xu et al., 1998).  
The GSTT1 and GSTM1 genes have two variants or 
polymorphisms, the wild type characterized by the 
presence of the enzyme and the null variant, 
characterized by the complete lack of enzyme activity 
(Rossini et al., 2002). The null alleles alter the response 
and toxicity of chemotherapy in patients with acute 
lymphoblastic leukemia, breast cancer and metastatic 
colorectal cancer (Goekkurt et al., 2006; Mossallam et al., 
2006; Valladares et al., 2006; Au et al., 2011).  
GSTP1 encodes for an enzyme that is highly 
expressed in epithelial tissue of lung, esophagus and 
placenta (Chávez, 2011). It presents three different 
polymorphisms: GSTP1*A, which is considered the wild 
type allele (Ile105; Ala114); GSTP1*B in which there is a 
base substitution located in the exon 5 at codon 104, 
resulting in a mutation of ATC (Ile) to GTC (Val); 
GSTP1*C presents a base substitution at codon 113 in 
exon 6 GCG (Ala) to GTG (Val) (Henderson and Wolf, 
2005; Custódio et al., 2010; Sharma et al., 2014). These 
changes reduce the enzyme activity (Chávez, 2011). 
It has been observed that patients with the same 
scheme of treatment show a lot of variability in the effect 
that treatment causes on them (Gonzalez et al., 2010). 





cause life-threatening toxicity. 
Pharmacogenomics studies the influence of genetic 
variations in the individual response to drugs (Steimer et 
al., 2002; Petros et al., 2005). This is due to the enzymes 
responsible of drug’s metabolism that, depending on the 
alleles present, may vary in expression, activity and 
function, therefore determining the cellular response to 
medical treatment. 
It has been demonstrated that a combination with other 
alleles of GST (GSTM1, GSTT1 and GSTP1) affect the 
response to treatment in patients with cancer (Bolt and 
Their, 2006; Oliveira et al., 2010; Wang et al., 2015), a 
clinical assessment is performed for the evaluation of 
response to this treatment after two to three cycles, using 
the system of the World Health Organization (WHO) or 
the RECIST system. Nowadays, it is impossible to know 
whether the therapy will be completely effective for the 
patient after the first application. The evaluation is made 
usually when half of the treatment has been 
administered, that is after a period of 4 to 5 months; at 
this moment patients not responding to the treatment will 
be detected, along with patients in whom the toxicity was 
too high to continue the scheme (Garibay et al., 2015). 
So it is important to clearly understand these 
mechanisms in order to use them as a platform for 
personalized therapies. 
The comet assay is a relatively inexpensive, fast, 
sensitive and reliable method to detect DNA breakage in 
individual cells. The most widely used cell type in this 
technique in lymphocytes, because they are easy to 
obtain and handle, and because they are continually 
exposed to xenobiotics that enter the body. This assay 
has positioned itself in a privileged position in the battery 
of biomonitoring studies used as a biomarker capable of 
demonstrating dose-effect relationships (Silva et al., 
2000). 
The aim of this investigation is to determine if the 
differences in the polymorphic genes of GST have an 
effect on the extent of DNA damage produced by 
cyclophosphamide in peripheral blood lymphocytes, 
which is related to the treatment response, in order to 








In this study, 120 individuals participated under previous 
informed consent. All of them were apparently healthy 
and belonged to the university community from Toluca de 
Lerdo, Estado de Mexico. Volunteers fluctuated from 17 
to 56 years old with an average age of 23.71 years; 48 of 
them were men and 72 women. This study was approved 
by the institutional ethics committee taking into account 







The first part of this work consisted in standardizing the 
comet assay methodology in order to evaluate 
lymphocyte DNA damage induced in vitro with 
cyclophosphamide. 
Whole blood samples were aseptically collected by 
venipuncture in heparinized tubes and labeled for 
identification. Blood was mixed with an equal volume of 
Hanks’ balanced saline solution (HBSS) and then 5 mL 
were carefully transferred to 5 mL of Ficol Hypaque 1083 
and centrifuged at 600xg for 10 minutes. The interphase 
ring of nucleated cells was collected, washed twice with 
HBSS, suspended in RPMI-1640 (Sigma, UK) 
supplemented with 10% FBS (Gibco, USA) and placed 
again at 37°C under a 5% CO2 atmosphere for 12 hours 
in a 25 cm
2 
cell culture flask. 
 
Genotoxicity assessment by means of the comet 
assay 
 
Cells were counted in a Neubauer chamber and diluted to 
a cell concentration of 8x10
5
 cells/mL Then, 100 µL 
aliquots were transferred to microtubes along with 100 µL 
of S9 microsomal fraction from rat liver treated with 
phenobarbital and B-naftoflavone; 4.5 mM of 
cyclophosphamide was added only to one tube. The 
samples were incubated for three hours at 37°C. 
After treatment, cells were spun down, the supernatant 
was discarded and the pellet was suspended in RPMI-
1640 and mixed with an equal volume of 1% low melting 
point agarose (LMPA) to a final concentration of 0.5%. 
Then 90 µL were poured on top of slides previously 
coated with a dried solution of 0.5% normal agarose (to 
serve as a frost), covered with coverslips and allowed to 
solidify for 1 minute. Afterwards, the coverslips were 
retired and the slides were immersed in cold lysis solution 
(99.5% DMSO, 100% Triton X-100) for one hour at 4°C. 
Next, the slides were transferred to an electrophoresis 
chamber, covered with electrophoresis solution (300 mM 
NaOH, 1 mM EDTA), at 4°C for 30 minutes to allow DNA 
unwinding and then a 20 V, 300 mAmp current was 
applied for 24 minutes. Slides were gently rinsed three 
times with neutralizing buffer (0.4 M Tris, pH7.5) and 
stained with 60 µL of ethidium bromide (20 µg/mL). 
Finally, slides were observed under a fluorescence 
microscope using a 515–560 nm (green light) excitation 
filter at 40x magnifying. One hundred cells per slide were 
examined and comet size was scored by means of the 
Comet Assay II Analyzer (Perceptive Instruments Inc.) 




Genomic DNA was obtained from whole blood by using 
the  Quick-g DNA Mini Prepkit (Zymo Research). GSTM1  
 




and GSTT1 polymorphisms were determined by multiplex 
PCR. The sequence of the primers used for GSTT1 was: 
forward 5´TCACCGGATCATGGCCAGCA3´ and reverse 
5´TTCCTTACTGGTCCTCACATCTC3´.The primers used 
for GSTM1 were: forward 
5´GAACTCCCTGAAAAGCTAAAGC3´ and reverse 
5´GTTGGGCTCAAATATACGGTGG3´ (Zhong et al., 
2006). As a positive control, albumin gene was amplified; 
the sequence used was: forward 
5´GCCCTCTGCTAACAAGTCCTAC3´ and reverse 
5´GCCCTAAAAAGAAAATCGCCAATC3´. The 
amplification settings were: initial denaturation 5 minutes 
at 95°C, denaturation 45 seconds at 95°C, alignment 45 
seconds at 57°C, final extension 45 seconds at 72°C for 
35 cycles. Subsequently, a horizontal electrophoresis 
was performed in 2% agarose gel to identify the presence 
of bands of 480 bp, 215 pb and 352 pb corresponding to 
GSTT1, GSTM1 and albumin respectively. Absence of 
DNA fragments of 480 bp and 215bp indicates null 
genotypes (Abdel et al., 1996). 
For GSTP1, polymorphisms were determined by using 
PCR-RFLP. For the GSTP1 exon 5, the sequence of the 
primers used was: forward 
5'ACCCCAGGGCTCTATGGGAA3' and reverse 
5'TGAGGGCACAAGAAGCCCCT3'. PCR settings were: 
initial denaturation 5 minutes at 95°C, denaturation 45 
seconds at 95°C, alignment 45 seconds at 61°C, final 
extension 45 seconds at 72°C for 35 cycles. For the 
GSTP1 exon 6,the sequence of the primers was: forward 
5´TGGCAGCTGAAGTGGACAGGATT3` and reverse 
5´ATGGCTCACACCTGTGTCCATCT3`, PCR settings 
were: initial denaturation 5 minutes at 95°C, denaturation 
45 seconds at 95°C, alignment 45 seconds at 57°C, final 
extension 45 seconds at 72°C for 35 cycles (Mejia et al., 
2013). 
The PCR products were verified by horizontal 
electrophoresis using 1.5% agarose gel. These products 
were then digested with BsmAI restriction enzyme for 
GSTP1 exon 5 and AciI for GSTP1 exon 6. These 
restriction enzymes recognize specifically the sequence 
variation in the alleles from the wild type, thus generating 
two fragments. Digestion products were separated by 
horizontal electrophoresis using a 2% agarose gel and 
stained with ethidium bromide. Genotype was identified 
based on the size of DNA fragments; for exon 5, a single 
176 bp band correspond to wild GSTP1*A wild type 
(Ile/Ile105), the 91 bp and 85 bp fragments correspond to 
GSTP1*B homozygous (Val/Val105) and the 176 bp, 91 
bp and 85 bp fragments correspond to GSTP1*B 
heterozygous (Ile/Val105). As for polymorphisms in exon 
6, the 332 bp fragment corresponds to homozygous 
GSTP1*C (Val/Val114); three fragments, of 332 bp, 174 
bp and 158 bp correspond to heterozygous GSTP1*C 
(Ala/Val114); and two fragments, 158 bp and 174 bp, 
indicate GSTP1*A wild type (Ala/Ala114) (Mejia et al., 
2013). 
 
















Assessment of the DNA damage produced by 
cyclophosphamide by means of the comet assay 
 
Figure 1 shows the mean tail length value of the control 
and treated lymphocytes. Overall, it can be seen that 
cyclophosphamide produced a large amount of DNA 
fragmentation in all the samples, however, it is quite 
evident that there is a great variation among them 
ranging from 63.25 to 224.23 µm while basal values are 
very similar from 10.19 to 20.24 µm. Statistical analysis 
using the t-paired test showed that there is a significant 
difference between both groups with a significance 




Figure 2 shows the frequency of each polymorphism of 
the 120 samples. GSTM1 genotypes percentages were 
56.67% GSTM1 wild type and 43.33% for GSTM1 null; 
GSTT1 showed a frequency of 62.5% for the GSTT1 wild 
type allele, while the GSTT1 null was 37.5%. The allelic 
frequency for exon 5 of GSTP1 was as follows: 20% wild 
type (Ile/Ile105); 45% heterozygote (Ile/Val105); 35% 
homozygote (Val/Val105). Interestingly, for exon 6 
GSTP1 all the donors presented the wild type genotype, 
so it was not possible to analyze the role of the 
polymorphism GSTP1*C homozygote or heterozygote in 
the sensitivity to cyclophosphamide. 




Table 1. Frequency of the 12 combined genotypes of GSTM1/ GSTT1/GSTP1 in the 120 
donors. 
 





1 21  (17.5) wt wt Ile/Val Ala/Ala 
2 15  (12.5) wt null Val/Val Ala/Ala 
3 13  (10.8) wt null Ile/Val Ala/Ala 
4 12  (10) null wt Val/Val Ala/Ala 
5 11  (9.2) wt wt Val/Val Ala/Ala 
6 11  (9.2) null wt Ile/Val Ala/Ala 
7 9    (7.5) wt null Ile/Ile Ala/Ala 
8 9    (7.5) null null Ile/Val Ala/Ala 
9 7    (5.8) null wt Ile/Ile Ala/Ala 
10 6    (5) wt wt Ile/Ile Ala/Ala 
11 4    (3.3) null null Val/Val Ala/Ala 
12 2    (1.7) null null Ile/Ile Ala/Ala 
 
wt: wild type.  
 
 
Table 2. Statistical comparison of DNA damage between type genotypes of GSTM1, GSTT1 and GSTP1. 
 
Gene Polymorphism n Tail length (µm) ± SD Statistical test p 
GSTM1 
wt 68 150.36 ± 35.73 
t-Student 0.800 
null 52 148.88 ± 28.25 
GSTT1 
wt 75 141.13 ± 32.38 
t-Student 0.077 
null 45 152.29 ± 33.47 
GSTP1 exon 5 
Ile/Ile 24 148.45 ± 38.74 
Anova 0.955 Ile/Val 54 150.67± 31.46 
Val/Val 42 149.21 ± 30.94 
GSTP1 exon 6 Ala/Ala 120 0 - - 
 
wt: wild type.  
Values of p≤0.05 are considered statistically significant 
 
 
Combined Genotypes of GSTM1/GSTT1/GSTP1 
 
Overall, 12 different genotypes were identified and 
numbers were assigned to them according to their 
frequency. Number 1 was the most frequent with 17.5% 
and it included GSTM1 wild type, GSTT1 wild type, 
heterozygote GSTP1 exon 5, GSTP1 wild type exon 6. It 
should be noted that genotype number twelve was only 
found in two individuals, i.e. 1.7% of the samples. The 
complete data is shown in Table 1 above. 
 
Relation between DNA damage and GST genotype 
 
The average tail length of the comet induced by 
cyclophosphamide was calculated individually and 
associated with the polymorphisms of each allele. The 
polymorphisms were compared by using the t-Student 
test. The results show that there are no significant 




same was true for wild and null GSTT1. For GSTP1 exon 
5, an ANOVA was made to analyze the differences in tail 
length between wild type (Ile/Ile105), heterozygote 
(Ile/Val105) and homozygote (Val/Val105). No significant 
differences were found between these allelic variations. 
Since all the donors have the wild type form of GSTP1 
exon 6 alleles, it was not included in the final analysis 
(Table 2 above). 
Interestingly, although there were no variations 
between the polymorphisms taken individually, 
differences were found when the full genotypes were 
analyzed. It was observed that the genotype with the 
smaller average tail length was number 10, comprising 
only the wild type alleles GSTM1 wild type, GSTT1 wild 
type, GSTP1 wild type exon 5, GSTP1 wild type exon 6. 
Meanwhile, the one with the longest tail length average 
was number 12 GSTM1 null, GSTT1 null, GSTP1 wild 
type exon 5, GSTP1 wild type exon 6.  
 
 








GSTT1/ GSTM1/ GSTP1 exon 5; exon 6 
Frequency (%) Tail length (µm) 
10 wt/wt/Ile/Ile;Ala/Ala 6(5) 111.31 
3 wt/ null / Ile/Val;Ala/Ala 13(10.8) 144.77* 
7 wt / null/ Ile/Ile;Ala/Ala 9(7.5) 145.25* 
5 wt/ wt/ Val/Val;Ala/Ala 11(3.3) 148.44* 
8 null/ null/ Ile/Val;Ala/Ala 9(7.5) 148.55 * 
2 wt / null / Val/Val;Ala/Ala 15(12.5) 148.87 
4 null/ wt/ Val/Val;Ala/Ala 12(10) 149.66* 
11 null/ null/ Val/Val;Ala/Ala 4(3.3) 151.30 
1 wt/ wt /Ile/Val;Ala/Ala 21(17.5) 152.38* 
6 null/ wt/ Ile/Val;Ala/Ala 11(3.3) 156.13* 
9 null/ wt/ Ile/Ile;Ala/Ala 7(5.8) 172.93* 
12 null/ null/ Ile/Ile;Ala/Ala 2(1.7) 188.63 
 
wt: Wild type 
*These data are statistically different from wild genotype ID 10, t Student, p≤ 0.05. 
 
 
Genotype number 10,which is the one with all wild type 
genes and the one with the highest enzymatic activity, we 
compared it against all of the remaining 11 using the t 
Student test.Significant difference was found versus 
genotypes 3, 7, 5, 8, 4, 1, 6, 9. Genotypes are organized 
according to tail length. Details of this analysis are shown 
in table 3 above. 
Genotypes were analyzed according to the similarity 
they presented. Numbers 4, 6, 8 and 9 have the GSTT1 
null genotype and genotype GSTP1 exon 6 wild null. 
Numbers 11 and 12 coincide in having null genotype 
GSTT1, GSTM1 and GSTP1 wild type exon 6. It should 
be noticed that these genotypes do not have statistically 
significant differences compared with the control 
genotype (GSTT1 wild type, GSTM1 wild type, GSTP1 
wild type exon 5, GSTP1 wild type exon 6). Genotypes 2, 
3, 7, presented the common genotype GSTT1 wild type, 
GSTM1 null and GSTP1 wild type exon 6. However, 
genotype number 2 did not present statistical difference 
compared to the control genotype (number 10), whereas 
genotypes 5 and 1 had GSTT1 wild type, GSTM1 wild 





The main effect of phosphoramide mustard, the active 
metabolite of cyclophosphamide, is the formation of 
adducts and crosslinks (García and Mandina, 2005; 
Arencibia et al., 2009). If cells were treated in the same 
conditions, phosphoramide mustard should be producing 
a similar amount of damage on all the samples, unless 
genetic differences among the donors would be 
regulating such damage. In this work, heterogeneity was 
observed  in  the  extent  of  DNA  damage   induced   by  
cyclophosphamide, which suggests that the genetic load 
of each individual, particularly of the genes involved in 
the metabolism of cyclophosphamide, regulate its effect. 
The genetic variations of genes that encode enzymes 
involved in the metabolism of cyclophosphamide can 
influence the response to treatment, as reported by 
Zhong et al., 2006, who mentioned that individuals who 
possess the allelic variant GSTP1*B, presented a 
significant increase in the risk of suffering short-term side 
effects from high doses of cyclophosphamide. 
As for the role of GTS polymorphisms in individuals 
with respect to their response to cyclophosphamide, 
statistical tests clearly show that there are no significant 
differences among all the samples when genes are 
analyzed individually. However, when the full GST 
genotype is considered, differences are evident (Wang et 
al., 2015). 
We identified 12 different genotypes in the studied 
population and, among them, we found one with a 
complete wild type (genotype number 10) which, 
according to previous reports would have a higher 
enzyme activity regarding all the other genotypes with 
polymorphic genes, where enzyme activities is lower or 
totally lost, in the case of null alleles. Interestingly, this 
genotype has the lowest tail length mean value. In 
individuals with wild type genotypes, the drug is 
eliminated more efficiently due to an increase in 
enzymatic activity. This can translate into less therapeutic 
effect. On the other hand, genotype null GSTM1, GSTT1 
null, GSTP1 exon 5 wild type, GSTP1 exon 6wild type 
(genotype number 12), presented the largest tail length 
value, meaning that in individuals with this GST alleles 
the drug would linger for longer, thus producing a larger 
amount of damage. This genotype could be considered 






treatment with cyclophosphamide (Soto et al., 2011). 
According to our results, patients with the null alleles 
for GSTM1 or GSTT1 and genotype GSTP1*B would 
have a better response to a cyclophosphamide treatment. 
Indeed, it has been reported that patients with ovarian 
cancer have a better prognosis when the null alleles of 
GSTM1 and GSTT1 are present (Wang et al., 2015). 
Other publications about breast cancer and acute 
lymphoblastic leukemia indicate that null polymorphisms 
in GSTM1 and GSTT1 are associated with a better 
response to drug treatments (Stanulla and Schaffeier, 
2005; Wang et al., 2015). It is important to consider that 
multiple enzymes of the GST family such as GSTA1, 
GSTT1, GSTM1, GSTP1 or other families such as CYP 
and ALDHs are involved in bioactivation, detoxification 
and influence the response and toxicity of 
cyclophosphamide. The results of this investigation 
demonstrate the heterogeneity in the response to 
damage induced by cyclophosphamide and, on the other 
hand, the participation of the genes GSTT1, GSTM1 and 
GSTP1 as modulators of this damage. However, more 
preclinical and clinical pharmacogenetic studies are 
needed to fully understand the mechanism of action, 
resistance and toxicity of cyclophosphamide in order to 





Cyclophosphamide is part of one of the most used drugs 
in the treatment against cancer. Response to treatment is 
often uncertain. This research proposes an option to 
predict the response to treatment with cyclophosphamide 
at an early stage of treatment, considering the gene 
formula of GSTT1, GSTM1 and GSTP1 of each individual 
and the use of the comet assay. Besides, personalized 
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